This study is not yet accepting patients

Comparison of Whole Body DWI to FDG PET

a study on Cancer, General Metastatic Cancer

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California
Dates
study started
completion around
Principal Investigator
by Thomas A Hope, MD
Headshot of Thomas A Hope
Thomas A Hope

Description

Summary

This is a single arm prospective trial that evaluates whole body diffusion weight imaging (DWI) compared to 18F-fludeoxyglucose (FDG) Positron Emission Tomography with Magnetic resonance imaging (PET/MRI) in participants with known metastatic cancer.

Official Title

Comparison of Whole Body DWI to FDG PET Using PET/MRI

Details

PRIMARY OBJECTIVE:

  1. Correlation of DWI and FDG to detect disease.

SECONDARY OBJECTIVE:

  1. Inter-reader variability of DWI interpretation by region.

OUTLINE:

Participants will be imaged at a single timepoint using whole body DWI concurrent with FDG PET/MRI within 60 days of receiving a non-FDG PET (either PET/CT or PET/MRI). There will be an optional PET/MRI performed within six months of the original study. Participants will be followed up through a medical records review for up to two years.

Keywords

Metastatic Cancer, Imaging Study, Neoplasm Metastasis, Fluorodeoxyglucose F18, Positron Emission Tomography combined with Magnetic resonance imaging (PET/MRI), Whole Body Magnetic Resonance Imaging with Diffusion-Weighted Imaging (WB-MRI-DWI), General Electric (GE) SIGNA PET/MR, Whole Body DWI plus FDG PET/MRI

Eligibility

You can join if…

Open to people ages 18 years and up

  1. Age ≥ 18 years.
  2. Non FDG PET imaging study scheduled to be performed within 60 days (before or after) of the research PET/MRI.
  3. Ability to understand a written informed consent document, and the willingness to sign it.
  4. Diagnosis of metastatic cancer.

You CAN'T join if...

  1. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.

Location

  • UCSF
    San Francisco California 94143 United States

Lead Scientist at UCSF

  • Thomas A Hope, MD
    Thomas Hope, MD, is the Vice Chair of Clinical Operations and Strategy in the Department of Radiology. He also serves as the Director of Molecular Therapy. He serves as Chief of Nuclear Medicine at the San Francisco VA Medical Center and as chair of the Cancer Center’s Molecular Imaging & Radionuclide Therapy Site Committee.

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT06630845
Study Type
Interventional
Participants
Expecting 30 study participants
Last Updated